Genmab A/S Sponsored ADR $GMAB Shares Sold by Avidity Partners Management LP

Avidity Partners Management LP trimmed its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 62.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,000 shares of the company’s stock after selling 156,100 shares during the period. Genmab A/S accounts for approximately 0.8% of Avidity Partners Management LP’s investment portfolio, making the stock its 28th biggest holding. Avidity Partners Management LP’s holdings in Genmab A/S were worth $2,834,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership grew its position in Genmab A/S by 36.6% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock worth $153,324,000 after purchasing an additional 1,334,919 shares during the period. Kestra Advisory Services LLC acquired a new stake in Genmab A/S during the 4th quarter worth about $96,000. CANADA LIFE ASSURANCE Co grew its position in Genmab A/S by 43.4% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 4,522 shares of the company’s stock worth $139,000 after purchasing an additional 1,369 shares during the period. Stifel Financial Corp grew its position in Genmab A/S by 78.1% during the 4th quarter. Stifel Financial Corp now owns 39,931 shares of the company’s stock worth $1,230,000 after purchasing an additional 17,510 shares during the period. Finally, Hudson Bay Capital Management LP grew its position in Genmab A/S by 22.6% during the 4th quarter. Hudson Bay Capital Management LP now owns 325,000 shares of the company’s stock worth $10,010,000 after purchasing an additional 60,000 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Trading Down 0.6%

GMAB stock opened at $25.08 on Friday. The company’s 50-day simple moving average is $26.76 and its 200-day simple moving average is $29.24. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. Genmab A/S Sponsored ADR has a 52-week low of $20.23 and a 52-week high of $35.43. The firm has a market cap of $15.64 billion, a P/E ratio of 19.00, a PEG ratio of 1.49 and a beta of 0.85.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GMAB. Wolfe Research began coverage on Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price target on the stock. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. HC Wainwright cut their price target on Genmab A/S from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Thursday, April 30th. Jefferies Financial Group began coverage on Genmab A/S in a research report on Tuesday, February 17th. They set a “buy” rating and a $41.50 price target on the stock. Finally, Weiss Ratings downgraded Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $37.93.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.